ALK and non-small cell lung carcinoma: Taken together, our results and those recently reported for the EML4-ALK fusion in NSCLC [24] indicate that ceritinib is not an option for treatment of patients harbouring the L1198F mutation in either the full length ALK or the EML4-ALK fusion protein.